Palomino net loss widens to $2.61 million in FY26 first half from FY25 first half
PALX•Six-month loss and cash use widen
For the six months ended June 30, net loss widened to $2.61 million from $595,752, with cash used in operations increasing to $2.24 million from $81,031.
Trading debut and private placement
Shares began trading on OTCQB on April 17; a private placement sold 4,243,853 shares for gross proceeds of $16.98 million at $4 per share.
First-half loss widens as expenses increase
Palomino Laboratories posted a net loss of $1.37 million for the quarter ended June 30, 2026, swinging from net income of $389,417 a year earlier.
Operating loss widened to $1.37 million from $337,445, as operating expenses climbed to $1.37 million from $337,445.
General and administrative and R&D costs rise
General and administrative costs rose to , while research and development expense was versus no expense a year earlier.
